Automating Biologics Prior Auth in California

The Landscape of Biologics Prior Authorization in California

Biologics, including TNF inhibitors, IL-17/23, IL-6, and JAK inhibitors, represent a substantial share of high-cost specialty drug prior authorizations. In California, these workflows are shaped by a diverse payer mix, encompassing state-specific Medicaid managed care and a broad commercial payer footprint. The administrative volume associated with these complex therapies is significant, as tracked by industry benchmarks like the CAQH Index for specialty pharmacy PA.

Key Challenges for Biologics PA Workflows in California

Providers in California frequently encounter challenges such as indication-specific PA criteria, stringent step therapy requirements, and evolving biosimilar substitution policies. Additionally, documenting specific screening requirements—like TB, hepatitis, and immunizations—and managing periodic re-authorization cycles for chronic treatments add layers of complexity, impacting both operational efficiency and patient care pathways.

Klivira's Intelligent Workflow for Biologics PA in California

• **Indication Classification:** Identifies the specialty and disease state from EMR diagnoses, ensuring alignment with payer-specific criteria common in California's diverse payer landscape.
• **Step Therapy Automation:** Pulls prior-line therapy history (e.g., csDMARDs for rheumatology, 5-ASA for IBD) to satisfy state-level and commercial payer requirements.
• **Biosimilar Substitution Routing:** Applies per-payer biosimilar mandates, dynamically adapting to specific payer policies across California's health plans.
• **Screening Documentation:** Extracts and documents necessary screening results (e.g., TB, hepatitis B/C, immunization status) directly from FHIR data for efficient submission.
• **Periodic Re-authorization:** Manages typical 6/12-month re-authorization cycles with continuous disease-activity and response documentation for chronic biologic treatments.
• **Medical-vs-Pharmacy Benefit Routing:** Accurately routes prior authorizations based on whether the agent falls under medical or pharmacy benefit, critical for high-cost biologics in a state with varied benefit designs.

State-Specific Considerations for Biologics PA Automation

California's regulatory environment and payer landscape necessitate a PA automation solution capable of adapting to state-level mandates and diverse commercial policy variations. While specific state laws vary, systems must be agile enough to incorporate evolving requirements, ensuring compliance and operational integrity across the spectrum of Medicaid managed care and commercial plans operating within California.

Seamless EMR Integration for Biologics Authorization

Klivira integrates directly with EMR systems using standards like SMART on FHIR, enabling the automated extraction of clinical data critical for biologics prior authorizations. This includes diagnoses, medication history, and lab results for screening requirements, significantly reducing manual data entry and improving the accuracy and completeness of PA submissions for specialty biologics.

The Klivira Advantage for California Providers

By leveraging Klivira's automation platform, California clinics, hospitals, and health systems can transform their biologics prior authorization processes. Our solution reduces administrative burden, accelerates patient access to critical therapies, improves revenue cycle performance, and enhances compliance posture by aligning submissions with complex payer and state-level requirements.